Immuron (ASX:IMC) shifts focus to therapeutic drug candidate

Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates. https://themarketherald.com.au/immuron-asximc-shifts-focus-to-therapeutic-drug-candidate-2022-08-19/

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.